(Q38933049)

7 September 2017

Modeling the hepatitis A epidemiological transition in Thailand (English)

1 reference

7 September 2017

0 references

1 reference

3

1 reference

7 September 2017

Thierry Van Effelterre

series ordinal

1

1 reference

PubMed ID

26657185

7 September 2017

Cinzia Marano

series ordinal

2

1 reference

PubMed ID

26657185

7 September 2017

language of work or name

English

0 references

publication date

1 December 2015

1 reference

7 September 2017

1 reference

7 September 2017

34

1 reference

7 September 2017

4

1 reference

7 September 2017

555-562

1 reference

Hepatitis A: Epidemiology and prevention in developing countries

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Challenges to mapping the health risk of hepatitis A virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Hepatitis A virus seroprevalence by age and world region, 1990 and 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Declining hepatitis A seroprevalence: a global review and analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Modelling the force of infection for hepatitis A in an urban population-based survey: a comparison of transmission patterns in Brazilian macro-regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

The need for an evidence-based decision-making process with regard to control of hepatitis A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Model-based projections of the population-level impact of hepatitis A vaccination in Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Seroprevalence of hepatitis A among Thai population residing near Myanmar border

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Declining trend in the seroprevalence of infection with hepatitis A virus in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Age-specific prevalence of hepatitis A virus antibody in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

The Declining Transmission of Hepatitis A in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

The important role of early diagnosis and preventive management during a large-scale outbreak of hepatitis A in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

An age-structured model for pertussis transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Decline of maternal hepatitis a antibodies during the first 2 years of life in infants born in Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Modelling age-dependent force of infection from prevalence data using fractional polynomials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Use of a catalytic model to estimate hepatitis A incidence in a low-endemicity country: implications for modeling immunization policies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Basic mathematical models for the temporal dynamics of HAV in medium-endemicity Italian areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

A dynamic model for assessing universal Hepatitis A vaccination in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

An individual-based model of hepatitis A transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Cost-utility of universal hepatitis A vaccination in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

Age-Specific Prevalence of Antibody to Rotavirus, Escherichia coli Heat-Labile Enterotoxin, Norwalk Virus, and Hepatitis A Virus in-a Rural Community in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.052

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.11.052

1 reference

7 September 2017

1 reference

PubMed ID

26657185